In-keeping with this, MED30 was recently identified as an upregulated gene in stomach cancer connected with cancer proliferative properties (Lee et al., 2015) and in development of cardiomyopathy in mice carrying a missense mutation in the first exon (Krebs et al., 2011). This evidence concerns the gene MED30 and cancer.